1-3 of 3
Sammicheli Stefano
Close
Sort by
Journal Articles

Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

Sammicheli Stefano, Camille Grandclement, Valentina Labanca, Stefania De Angelis, Carole Estoppey, Myriam Chimen, Blandine Pouleau, Perrine Suere, Emilie Nallet, Ankita Srivastava, Eric J. Feldman, Igor Proscurshim, Cyril Konto, Eugene Zhukovsky, Mario Perro
Journal: Blood
Blood (2022) 140 (Supplement 1): 6237–6238.
https://doi.org/10.1182/blood-2022-162201
Published: 2022
Journal Articles

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Hanlon Sia, Peter T. Tan, Joshua Richter, Phoebe Joy Ho, Tara Cochrane, Hang Quach, Binod Dhakal, Igor Proscurshim, Tony Jiang, Emaryn Mancino, Yacine Salhi, Sammicheli Stefano, Girish Gudi, Andrew Garton, Eric J. Feldman, Andrew Spencer
Journal: Blood
Blood (2022) 140 (Supplement 1): 10182–10184.
https://doi.org/10.1182/blood-2022-157585
Published: 2022
Journal Articles

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

Sammicheli Stefano, Camille Grandclement, Elie Dehilly, Maria Panagopoulou, Evangelia Martini, Rosa Castillo, Perrine Suere, Blandine Pouleau, Carole Estoppey, Julia Frei, Jeremy Loyau, Thierry Monney, Rebecca Wood, Amelie Croset, Alain Rubod, Girish Gudi, Venkatesha Udupa, Sunitha Gn, Vinu Menon, Daniel Rasmussen, Jeppe Koch Olsen, Roberto Giovannini, Aravind Chakrapani, Stanislas Blein, Marie-Agnes Doucey, Adam Drake, Alessandro Riva, Cyril Konto, Mario Perro, Lamine Mbow
Journal: Blood
Blood (2021) 138 (Supplement 1): 73.
https://doi.org/10.1182/blood-2021-145586
Published: 2021